# Dentsply Sirona to Host Second Quarter Conference Call on August 6th
Canonical URL: https://biopharmsignal.com/news/XRAY/dentsply-sirona-to-host-second-quarter-conference-call-on-august-6th-21fd2675
Ticker: XRAY
Company: DENTSPLY SIRONA Inc.
Source: DENTSPLY SIRONA Inc.
Published: 2026-07-21 20:15 EST
## Summary

DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the...

## Article Body
DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, August 6, 2026, at 4:30 p.m. ET to review its second quarter 2026 financial results. Financial earnings materials will be made available on the Investors section of the Company’s website at https://investor.dentsplysirona.com prior to the call.

Conference Call / Webcast Information

The live webcast link and call information will be available on the Investors section of the Company’s website at https://investor.dentsplysirona.com. For those planning to participate on the call, please register here . A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call.

About Dentsply Sirona

Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona’s innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

Contact Information

Investors: Wade Moody Senior Manager, Investor Relations Investorrelations@dentsplysirona.com
## Recent Company News
- 2026-07-28 12:30 EST — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2) — Source: DENTSPLY SIRONA Inc.
- 2026-07-21 20:15 EST — [Dentsply Sirona to Host Second Quarter Conference Call on August 6th](https://biopharmsignal.com/news/XRAY/dentsply-sirona-to-host-second-quarter-conference-call-on-august-6th-21fd2675) — Source: DENTSPLY SIRONA Inc.
- 2026-07-01 21:00 EST — [PDS Health Surpasses Five Million CEREC Chairside Restorations with Dentsply Sirona, Marking a Major Milestone in Scaled Digital Dentistry](https://biopharmsignal.com/news/XRAY/pds-health-surpasses-five-million-cerec-chairside-restorations-with-dentsply-sir-7db929d4) — Source: DENTSPLY SIRONA Inc.
- 2026-06-11 12:30 EST — [Dentsply Sirona Appoints John Fortson as Chief Financial Officer](https://biopharmsignal.com/news/XRAY/dentsply-sirona-appoints-john-fortson-as-chief-financial-officer-fc7266be) — Source: DENTSPLY SIRONA Inc.
- 2026-05-26 20:30 EST — [Dentsply Sirona Continues to Expand U.S. Distribution Network to Strengthen Access to its Digital Dentistry Solutions Across Key Regional Markets](https://biopharmsignal.com/news/XRAY/dentsply-sirona-continues-to-expand-u-s-distribution-network-to-strengthen-acces-23141708) — Source: DENTSPLY SIRONA Inc.
## Related News
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)
- 2026-07-28 12:05 EST — GSK — [GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK](https://biopharmsignal.com/news/GSK/gsk-to-establish-new-flagship-r-d-centre-on-cambridge-biomedical-campus-uk-6f2bb859)